The day, Pfizer and BioNTech vaccines were approved by the Centers for Disease Control and Prevention (CDC), the world saw a ray of light at the end of the tunnel. The work on the vaccine was started since the Trump era, but it came to fruition when President Biden took over office. Soon, after presiding the office, the current president ordered the fair distribution of these vaccines among the Americans as soon as possible.
To get the favorable results of the vaccination, one must take two doses with a gap of at least two weeks. Seeing the situation, and the aim to distribute vaccines among as many people as possible, the federal authorities were unable to provide the second dosage. Moreover, many Americans have still not gotten their first dosage.
With the new strains that came from the UK and South Africa, the researchers are still unsure, if the already developed vaccine will also work on them or not. Although we have come a long way and are on the verge of success to combat the global pandemic, the cases are again on the rise. The current rate is alarming and demands quick vaccination for Americans.
Not only the process of vaccine distribution is challenging, but this is also void because the vaccine will not work effectively if only one dose is administered.
However, according to Pfizer and BioNTech, there would be enough vaccines available for everyone by the end of 2021. Moreover, Countries like China and Russia have also come up with vaccines. But their vaccines are yet to go through phase three trials. Once the vaccines clear the trials successfully, it will make vaccine distribution easier around the world.
With many companies coming up with vaccines, the potential threat of them getting rejected due to legitimacy can prove to be a hurdle for the distribution phase.
Other than this, the certification, documentation, and manufacturing of the vaccines dominated by the countries will also lead to discussions among other nations. According to the Northeastern University, if the 50 developed countries receive the initial 2 billion vaccine dosages, it would help in saving the lives of 33% of the world’s population.
However, this depends on the availability of the vaccines. If the supply is limited, the countries have to come up with even grounds to eradicate the problem from the roots.
All in all, the development of vaccines surely shows the silver lining, but the distribution of them will not be easy. The global community must join their hands to bring the crises to an end.
